A transcript of the video narration is below:
Hello this is Nathan Radcliffe, MD, chief medical editor of Glaucoma Physician, and I’m here at the American Glaucoma Society meeting in 2025. I just had the privilege of presenting and launching the direct selective laser trabeculoplasty Voyager from Alcon. This is an evolution, or perhaps even a revolutionary new type of laser trabeculoplasty, which is automated. It involves no contact, so there’s no need for a gonioscopy or a gonioscopic lens or coupling agent and it can provide selective laser trabeculoplasty in an ergonomic and patient-friendly way.
We talked about the need for more laser trabeculoplasty given the fantastic evidence of its efficacy [and] with laser trabeculoplasty finding its role now as the primary therapy for open-angle glaucoma. Given that so many patients will need to have laser trabeculoplasty, there’s a need for us to do it in a more efficient way, and the Voyager DSLT is going to do a fantastic job of addressing that unmet need.
I reviewed some of the data, which met noninferiority to traditional SLT at 6 months and showed excellent efficacy and safety out to 12 months, and my colleagues and I discussed how we’ve integrated this laser into our practice. Our experience has been very positive and the patients’ experience has been positive—particularly for patients who’ve had both types of laser. Overall, we believe that this therapy is much needed and that it should accelerate interventional glaucoma, which really should begin with laser trabeculoplasty as the first treatment for our glaucoma patients. Thank you for listening. GP
